Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037230 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02037230 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 34 participants.
The verdict
NCT02037230, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The investigators' long-term goal is to improve the survival of patients with pancreatic cancer by enhancing the efficacy of gemcitabine-radiation by adding the Wee1 inhibitor MK-1775.
Interventions
- RADIATION Radiation Therapy
- DRUG Gemcitabine
- DRUG MK-1775
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02037230
The ClinicalTrials.gov registry entry for NCT02037230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT02037230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02037230 about?
NCT02037230 is a clinical study titled "Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas". The investigators' long-term goal is to improve the survival of patients with pancreatic cancer by enhancing the efficacy of gemcitabine-radiation by adding the Wee1 inhibitor MK-1775.
What is the current status of trial NCT02037230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2014-01. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02037230?
The interventions under investigation include: Radiation Therapy (RADIATION), Gemcitabine (DRUG), MK-1775 (DRUG).
Who is sponsoring clinical trial NCT02037230?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.